Using the EQ-5D Health Index during the course of treatment, this study compares patient-reported general health status during treatment with palbociclib (a cyclin-dependent kinase 4/6 inhibitor) plus fulvestrant (a complete estrogen receptor antagonist) compared with during treatment with fulvestrant alone.
Exploring the Relationship Between Progression-Free Survival and Overall Survival in Breast Cancer Patients Treated with Fulvestrant or Anastrozole
Progression-free survival (PFS) is often used as a surrogate for overall survival (OS) due to the challenges of measuring OS in relatively short-term trials, and is a practice that has been supported by previous analyses of breast cancer data. This analysis further examines the relationship between PFS and OS in advanced breast cancer.
Eribulin mesylate is an inhibitor of microtubule dynamics that may play a role in reducing the abnormality of the tumor microenvironment (ie, increasing oxygenation). As hypoxic conditions may contribute to drug resistance, it is hypothesized that eribulin may enhance the efficacy of other therapies. In this study, the effects of eribulin on 2 endocrine therapies were evaluated.
In a retrospective study of 45 breast cancer patients, the differential expression of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, and Ki-67 is evaluated in primary and relapsed tumors. The conversion rate of these biomarkers and their prognostic relevance are assessed.
Exploratory Biomarkers in MONARCH 1: A Phase 2 Study of Abemaciclib Monotherapy in HR+/HER2– Metastatic Breast Cancer
In this study, patients with advanced hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2–) breast cancer that have disease progression following antiestrogen therapy are treated with abemaciclib (a selective inhibitor of cyclin-dependent kinases 4 and 6) as a monotherapy. Exploratory biomarkers identified during this study are presented.
Next-Generation Sequencing Reveals Molecular Subtypes Beyond Those Defined by Hormone Receptor Expression
Breast carcinomas can be classified into 4 subtypes based on their hormone receptor expression: basal, luminal A, luminal B, and human epidermal growth factor receptor 2 overexpressed. This study uses comprehensive genomic profiling to further stratify tumors by their predicted sensitivity to a variety of therapies.
Everolimus, an inhibitor of mammalian target of rapamycin, is approved for use in the United States and European Union in combination with exemestane (an aromatase inhibitor) for the treatment of postmenopausal women with advanced estrogen receptor–positive/human epidermal growth factor receptor 2–negative breast cancer. This retrospective study evaluates the patterns of care and complications associated with this treatment over a 5-year period (2009-2014).
Circulating Tumor Cell Counts May Have Prognostic Value in Determining First-Line Therapy in HR+/HER2– Metastatic Breast Cancer
In patients with hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2–) metastatic breast cancer, the decision to treat first with hormone therapy or chemotherapy can be made at the discretion of the attending oncologist, or by taking into account the number of circulating tumor cells. This phase 3 study compares the outcome of these 2 methods.
Preliminary Safety and Efficacy of TAK-228 plus Exemestane or Fulvestrant in ER+/HER2– Metastatic Breast Cancer
TAK-228 is an investigational, oral, highly selective, ATP-competitive inhibitor of TORC1/2. By mitigating feedback within the PI3K/AKT/mTOR pathway, TAK-228 may restore sensitivity to endocrine therapies in patients who have progressed on such agents in combination with everolimus. This phase 1b/2 study evaluates the safety, pharmacokinetics, and preliminary efficacy of TAK-228 in combination with exemestane or fulvestrant.
Fulvestrant (a complete estrogen receptor [ER] antagonist) represents an endocrine therapy for patients with ER-positive metastatic breast cancer who have disease progression after treatment with an antiestrogen. This study evaluates the clinical benefit rate of fulvestrant 500 mg monthly, defined as complete response, partial response, or stable disease lasting >24 weeks, in women with locally advanced breast cancer.
The objective of this study is to evaluate the efficacy and safety of everolimus (an inhibitor of mammalian target of rapamycin) in combination with letrozole (an aromatase inhibitor) in postmenopausal women with advanced estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2–) breast cancer.
PM01183 (lurbinectedin) is an investigational compound that blocks transactivated transcription and induces the formation of double-strand breaks in a range of cancer lines. This study is designed to evaluate whether the presence of BRCA1/2 mutations can act as a prognostic indicator of response to PM01183 in patients with metastatic breast cancer.
This study is designed to compare treatment with palbociclib (a cyclin-dependent kinase 4/6 inhibitor) in combination with letrozole (an aromatase inhibitor) versus placebo with letrozole in postmenopausal women with estrogen receptor–positive (ER+)/human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer. A secondary outcome measure of the study, the analysis of tumor tissue biomarkers, is presented here.
Fulvestrant is a complete estrogen receptor (ER) antagonist currently approved for the treatment of ER-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy. This phase 3 study compares first-line fulvestrant with anastrozole (an aromatase inhibitor) in postmenopausal women with ER-positive and/or progesterone receptor–positive advanced breast cancer.
The French SIGNAL and PHARE projects have collected data on more than 9800 patients with breast cancer since 2006. In evaluating the outcomes of sequential and concomitant administration of trastuzumab within this cohort, this study provides insight into the ideal administration protocol for patients with human epidermal growth factor receptor 2–positive (HER2+) breast cancer.
The 21-gene Recurrence Score® is the result of a commercial genomic test that evaluates the likelihood that breast cancer will recur, and the likely benefit from chemotherapy and/or radiation therapy. This study evaluates disparities in hormone receptor–positive (HR+) breast cancer outcome by age and 21-gene Recurrence Score®.
Previous studies have reported that an elevated neutrophil-to-lymphocyte ratio is associated with an increased risk of relapse and worse survival in women with breast cancer. Additional data about the prognostic role for this biomarker in patients with early breast cancer are presented here.
In this ongoing phase 2 study, postmenopausal women with hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2–) breast cancer are being treated with abemaciclib (a selective inhibitor of cyclin-dependent kinases 4 and 6), anastrozole (an aromatase inhibitor), or both simultaneously.
Results from an open-label, randomized phase 3 trial evaluating the effects of panitumumab plus best supportive care versus best supportive care alone in chemorefractory, wild-type KRAS exon 2 and wild-type RAS metastatic colorectal cancer.
Results from a phase 1b study of the cancer stem-cell pathway inhibitor BBI608 in combination with FOLFIRI ± bevacizumab in patients with advanced colorectal cancer.
NEO-102, an Anti-MUC5AC Monoclonal Antibody, in Chemotherapy-Refractory Metastatic Colorectal Cancer
Initial results from a phase 2 open-label study of NEO-102, a novel chimeric monoclonal antibody targeting a variant of MUC5AC, in patients with chemotherapy-refractory metastatic colorectal cancer.
Results from STEAM, an open-label, randomized, phase 2 study of sequential versus concurrent FOLFOXIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer.
Results from the phase 1b JAVELIN study of the anti–PD-L1 monoclonal antibody avelumab in patients with advanced gastric or gastroesophageal junction cancer, stratified based on the level of PD-L1 expression.
Results of an open-label phase 1/2 study evaluating the safety and efficacy of nivolumab monotherapy for patients with advanced gastroesophageal or gastric cancer.
Results of the phase 1b KEYNOTE-028 study of pembrolizumab in PD-L1+ advanced esophageal carcinoma.
Investigation of the role of the mTOR pathway on the stemness of a putative cancer stem- cell population in esophageal cancer.
Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Results from RAINBOW, a randomized phase 3 trial of the safety and efficacy of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastroesophageal junction adenocarcinoma.
An in vitro study to determine whether inactivation of the Notch and wnt-beta-catenin pathways is crucial for cancer stem-cell development and if such a therapeutic approach with a γ-secretase inhibitor would be effective in treating patients with gastric cancer.
Results from a phase 1b study of the anticancer stem-cell agent demcizumab plus gemcitabine with or without nab-paclitaxel in the first-line treatment of patients with pancreatic cancer.
Results from a phase 1b study of the cancer stem-cell pathway inhibitor BBI608 plus gemcitabine and nab-paclitaxel in treating patients with metastatic pancreatic ductal adenocarcinoma.
Results of a clinical trial to determine if transcatheter chemoembolization, radiofrequency ablation, and cryoablation can enhance the effect of the CTLA-4 inhibitor tremelimumab in treating patients with hepatocellular carcinoma or biliary tract carcinoma.
Safety and efficacy results of a phase 2 trial assessing outcomes of patients with resected pancreatic adenocarcinoma treated with gemcitabine plus cisplatin and stratified by tumor excision repair cross-complementing gene-1 (ERCC1).
Results of a phase 1b/2 study of the safety and efficacy of the cancer stem-cell inhibitor BBI608 plus paclitaxel in treating patients with advanced pancreatic cancer.
Oncologists looking to learn about immunotherapy didn’t have to go very far at the American Society of Clinical Oncology Annual Meeting. Many of the highest-impact presentations this year, including a plenary session abstract, the Karnofsky Award, and the Science of Oncology Award, focused on cancer therapy’s most exciting field.
The final day of the 2015 Fourth Annual World Cutaneous Malignancies Congress (WCMC) opened with a review of yesterday’s presentations by the meeting chair, Dr. Sanjiv Agarwala. He stressed the multidisciplinary nature of the day’s proceedings that makes WCMC unique among cutaneous malignancy conferences.
Chaired by Dr. Sanjiv Agarwala, and with an advisory committee that included Drs. Axel Hauschild, Aleksandar Sekulic, Madeleine Duvic, and Paul Nghiem, the Fourth Annual World Cutaneous Malignancies Congress will feature multidisciplinary perspectives on skin cancer.
The second day of the 2015 Fourth Annual PMO Live Conference of the Global Biomarkers Consortium (GBC) opened with a review of yesterday’s presentations and a preview of today’s talks by the meeting’s co-chair, Dr. Hope Rugo. She stressed the multidisciplinary nature of the day’s proceedings that makes GBC unique among molecular biomarker/personalized medicine conferences.
Welcome to the 2015 Fourth Annual PMO Live Conference, a joint program of the Global Biomarkers Consortium (GBC) and the World Cutaneous Malignancies Congress. The GBC, whose theme is “Molecular Biomarkers for Precision Medicine in Oncology: Recent Advances and Future Perspectives,” consists of a community of world-renowned healthcare professionals, assembled to explore the clinical application of novel molecular pathways and prognostic and predictive molecular biomarkers in oncology, leading to delivery of personalized care for cancer patients.
Updates from the 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO) from the publishers of Value-Based Cancer Care, that focus on the most recent data on existing and emerging agents for the treatment of patients with NSCLC.
As anticipated, Tuesday proved to be a great day of education and inspiration for guests of the AONN+ West Coast Regional Meeting. In signature fashion, Lillie D. Shockney, RN, BS, MAS, AONN+ Program Director, set the tone for the day with a welcome that was both warm and humorous.
The sessions conducted on May 5, 2015, were co-chaired by Barbara McAneny, MD, and Sanjiv Agarwala, MD. The day’s focus was particularly relevant for cancer care providers, with topics ranging from novel payment models to next-generation sequencing (NGS).
The final day of the Third Annual PMO Live Conference, a Global Biomarkers Consortium Initiative, opened with a review of yesterday’s presentations and a preview of today’s talks by the meeting’s co-chair, Dr. Jorge Cortes. He stressed the multidisciplinary nature of the day’s proceedings that makes PMO Live unique among molecular biomarker/personalized medicine conferences.
The Third Annual PMO Live Conference, a Global Biomarkers Consortium Initiative, opened today with a record turnout. More than 100 registrants were welcomed by Dr. Roy Herbst, Chief of Medical Oncology at the Yale Comprehensive Cancer Center, one of the Congress co-chairs. Dr. Herbst provided an overview of the exciting new developments in the molecular pathophysiology and personalized therapy of cancer, and laid out the goals of the meeting.
The final day of the Third Annual World Cutaneous Malignancies Congress (WCMC) opened with a Breakfast Product Theater titled “Management of Early-Stage (IA and IB) Mycosis Fungoides–Type Cutaneous T-Cell Lymphoma (MF-CTCL) and VALCHLOR Clinical Overview,” presented by Dr. Larisa Geskin and sponsored by Actelion.
The Third Annual World Cutaneous Malignancies Congress (WCMC) opened today with a record turnout with more than 150 registrants welcomed by the Congress chair, Dr. Sanjiv Agarwala.